Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Orthofix makes and sells medical devices and biologic products used in spine and orthopedic surgery.
Orthofix is a medical device company that builds the hardware and biologic materials surgeons use when they fix a spine or repair a broken bone. Its products fall into two broad buckets: the metal implants and instruments used in spine surgery, and the external and internal fixation devices plus bone-growth biologics used to help orthopedic injuries heal. The people who actually use these products are surgeons, and the people who pay for them are mostly hospitals and surgery centers, usually through insurance.
In spine surgery, the company sells the screws, rods, plates, and cages that hold vertebrae in place while they fuse, along with the tools and guidance systems that help a surgeon place them accurately. In orthopedics, it is best known for external fixation — a frame that sits outside the body and holds broken bones steady while they mend — and for bone-growth stimulation devices and biologics that encourage stubborn fractures to heal. Surgeons choose a vendor like Orthofix because the implant has to fit the anatomy, the instruments have to feel right in the hand, and the sales rep has to be in the room when something is needed. That last part matters: this is a relationship-and-service business as much as a product business. The competitive field is crowded and dominated by much larger players. Medtronic and Stryker are big in spine, Johnson & Johnson's DePuy Synthes unit sells spine and trauma hardware, and Zimmer Biomet competes in orthopedics. Orthofix is a smaller challenger, which means it wins on niche products and surgeon loyalty rather than scale. The company itself became bigger through a merger: in 2023 it combined with SeaSpine, a spine-focused business, which broadened its spine lineup and its sales reach. That merger has also been messy. Orthofix has had leadership turmoil since the deal, including the abrupt removal of its CEO and other executives in 2023 over conduct issues, and the stock has been volatile. The business is not a cash machine like a software company — medical device companies spend heavily on product development, regulatory approval, and a direct sales force, and they carry the constant risk that a competitor's implant or a cheaper alternative wins the surgeon's preference. Still, the underlying demand is durable: people keep aging, backs keep wearing out, and bones keep breaking.
What makes Orthofix interesting is that it sits in the unglamorous, high-friction part of medicine — the operating room. Its products are not consumer brands and most patients never hear its name, but the company's fate depends on whether surgeons trust its implants and whether hospitals keep buying them. That is a slow, competitive grind, and Orthofix is a small player trying to hold its ground against giants.
Saved answer · last researched 16 Nov 2026